Stock-Based Compensation

9 Months Ended

Mar. 31, 2021

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

(10) Stock-Based Compensation

Stock Option Activity Summary

The Company’s stock option activity for the nine months ended March 31, 2021 is as follows:

	Shares (in thousands)			Weighted Average Exercise Price
Outstanding at June 30, 2020		325		$	5.68
Granted		50			5.00
Exercised		—			—
Canceled or expired		(4	)		5.19
Outstanding at March 31, 2021		371		$	5.59

The aggregate intrinsic value of options exercisable at March 31, 2021 was $0, as the fair value of the Company’s common stock is less than the exercise prices of these options. The remaining stock-based compensation expense of $88 thousand related to stock options will be recognized over a weighted-average period of 2.96 years.

The table below details the Company’s stock options outstanding as of March 31, 2021:

Range of exercise prices	Number Outstanding		Options Outstanding Weighted- Average Remaining Contractual Life (years)		Weighted- Average Exercise Price		Number Exercisable		Options Exercisable Weighted- Average Exercise Price
$1.85 – 3.55		76,300		2.03	$	3.43		69,634	$	3.35
$5.00 – 5.85		164,725		7.29		5.43		113,203		5.49
$6.00 – 8.35		130,000		3.65		7.19		86,000		6.59
$1.85 – 8.35		371,025		4.93	$	5.59		268,837	$	5.29

Compensation costs recognized related to stock option awards were $0 and $43 thousand for the three months ended March 31, 2021, and 2020, respectively and $1 thousand and $128 thousand for the nine months ended March 31, 2021 and 2020, respectively.

Restricted Stock

The Company’s restricted stock activity for the nine months ended March 31, 2021, is as follows:

	Shares (in thousands)			Weighted Average Grant-Date Fair Value
Outstanding at June 30, 2020		133		$	3.95
Granted		2,019			2.02
Vested		(58	)		1.84
Canceled or expired		(23	)		5.40
Outstanding at March 31, 2021	$	2,071		$	2.07

Stock compensation expenses related to restricted stock were $194 thousand and $52 thousand for the three months ended March 31, 2021, and 2020, respectively and $284 thousand and $154 thousand for the nine months ended March 31, 2021 and 2020, respectively. The remaining stock-based compensation expense of $4.2 million related to restricted stock awards granted will be recognized over a weighted-average period of 2.93 years.